« Return to News | Awards & Advancement

Merrimack raises $77 million for cancer therapeutics

Thursday, April 14, 2011 12:26 PM

Massachusetts-based Merrimack Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of treatments for cancer, has raised $77 million in a Series G private financing with participation by new and existing investors. Proceeds from the financing will be used to advance the company’s pipeline cancer therapeutics, according to Fierce Biotech. 

Some of the company’s most advanced product candidates are MM-398, a nanoliposomal formulation of irinotecan, currently in three phase II trials, MM-121, an ErbB3 antagonist, currently in four phase I/II trials, and MM-111, a bispecific antibody targeting ErbB2/ErbB3, currently in three phase 1/II trials.

"Over the last 10 years, our investors have been a critical force to help us build a biopharmaceutical company based on a systems approach to drug discovery and development," said Robert Mulroy, president and chief executive officer. "We are excited to add more quality investors who are aligned with our vision to create transformative medicines and diagnostics to benefit cancer patients everywhere."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.